Eledon Pharmaceuticals (ELDN) Current Assets (2013 - 2026)

Eledon Pharmaceuticals has reported Current Assets for 14 years, with the latest figure at $113.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 11.07% year-over-year to $113.6 million; the trailing twelve-month figure through Mar 2026 stood at $113.6 million (down 11.07% YoY), and the FY2025 full-year result was $135.7 million, down 5.6% from the prior year.
• Current Assets for Q1 2026 stood at $113.6 million, down from $135.7 million in the prior quarter.
• The five-year high for Current Assets was $143.7 million in Q4 2024, with the low at $48.0 million in Q1 2024.
• Historically, Current Assets has averaged $86.2 million across 5 years, with a median of $79.3 million in 2022.
• Annual changes were most pronounced in 2023 — Current Assets slumped 38.35% — and 2025, when it surged 166.21%.
• Eledon Pharmaceuticals' Current Assets stood at $59.5 million in 2022, then retreated by 5.69% to $56.1 million in 2023, then jumped by 156.07% to $143.7 million in 2024, then retreated by 5.6% to $135.7 million in 2025, then retreated by 16.3% to $113.6 million in 2026.
• The last three Current Assets figures came in at $113.6 million (Q1 2026), $135.7 million (Q4 2025), and $96.3 million (Q3 2025), per Business Quant data.